To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

Within the next decade, routine screening and preventive care for Alzheimer's disease could become a reality, say researchers ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...

The agency maintains that the beta-amyloid-targeting drugs show too limited benefit to justify their cost to the National Health Service.

A newly approved Alzheimer’s drug is set to be administered for the first time in Taiwan on Monday, Far Eastern Memorial Hospital in New Taipei City announced yesterday. Kisunla, the brand name of the ...

And other biotech news brought to you by The Readout.

Eli Lilly (NYSE:LLY) announced it would appeal a decision by the U.K. health authorities not to recommend the company’s new ...

Microsoft co-founder Bill Gates reflects on his father's Alzheimer's battle and expresses optimism about advancements in ...

New da­ta on an in­jectable form of Ei­sai’s Alzheimer’s drug, Leqem­bi, showed that it was more ef­fec­tive than an in­tra­venous ver­sion at clear­ing amy­loid but … ...

TAIPEI (Taiwan News) — Far Eastern Memorial Hospital is set to become the first medical institution in Taiwan to administer ...

The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

The benefits from Eli Lilly’s Kisulna (donanemab) remain too small to justify the additional cost to the National Health Service (NHS), said the UK health technology assessor the National Institute ...